Clinical Trial Update: A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating CagriSema for weight loss in East Asia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity or Overweight | Phase 3 | Status: COMPLETED